Amendments to the Claims

5

11. (Currently Amended) A compound of formula (I)

$$\begin{array}{c|c}
R^1 & R^2 \\
\hline
A & N & R^3
\end{array}$$

(I)

10

wherein:

A represents a group of formula (a) or (b) or (c):

15

20

25

R¹ and R² independently represent H, C1 to 8 alkyl, C2 to 8 alkenyl, C2 to 8 alkynyl or C3 to 7 saturated or partially unsaturated cycloalkyl; the latter four groups being optionally further substituted by one or more groups selected independently from OH, C1 to 6 alkoxy, CH₂OR⁴, NR⁵R⁶, CO₂R⁷ and CONR⁸R⁹;

R³ represents C1 to 6 alkyl, C2 to 6 alkenyl, C2 to 6 alkynyl or C3 to 7 saturated or partially unsaturated cycloalkyl; said alkyl, alkenyl or alkynyl chain optionally including a O, NR¹⁰ or S atom in the chain; said alkyl, alkenyl, alkynyl or cycloalkyl group being optionally substituted by phenyl or a 5 or 6 membered heteroaromatic ring containing 1 to 3 heteroatoms selected independently from O, S and N; said phenyl or heteroaromatic ring being optionally further substituted by one or more groups selected independently from halogen, C1 to 4 alkyl, OH, C1 to 4 alkoxy, CN, CO2R¹¹ CO2R¹¹, NR¹²R¹³, CONR¹⁴R¹⁵, SO2R¹⁶, NR¹⁷SO2R¹⁸ and SO2NR¹⁹R²⁰;

X represents O or S(O);

5

10

$$R^{21}$$
 represents H, CH_2OR^{24} , $CH_2NR^{24}R^{25}$, CO_2R^{24} or $CONR^{24}R^{25}$;

R²² and R²³ are independently represent H, C1 to 6 alkyl, C2 to 6 alkenyl or C3 to 7 saturated or partially unsaturated cycloalkyl; said alkyl, alkenyl or cycloalkyl group being optionally substituted by OR²⁴, NR²⁴R²⁵, CO₂R²⁴ or CONR²⁴R²⁵; or the group NR²²R²³ together represents a 3 to 7 membered saturated azacyclic ring optionally incorporating one further heteroatom selected from O, S(O)_n and NR²⁶; and optionally substituted by OR²⁴, NR²⁴R²⁵, CO₂R²⁴ or CONR²⁴R²⁵;

n represents an integer 0, 1 or 2;

15 R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , R^{24} , R^{25} and R^{26} independently represent H or C1 to 6 alkyl;

and pharmaceutically acceptable salts thereof.

- 20 12. (Currently Amended) A compound according to Claim 11 wherein R¹ represents H or CH₃.
 - 13. (Currently Amended) A compound according to Claim 11 wherein R² represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or CH₂OR⁴.
- 14. (Currently Amended) A compound according to Claim 11 wherein R³ represents C1 to 2 alkyl substituted by phenyl; said phenyl being optionally substituted by halogen, C1 to 6 alkoxy or CN.
- 30 Claim 15 (Cancelled)
 - 16. (Currently Amended) A pharmaceutical formulation comprising a compound of formula (I), as defined in Claim 11 or a pharmaceutically acceptable salt thereof, optionally in admixture with a pharmaceutically acceptable diluent or carrier.

```
21. (New)
                   A compound selected from:
     (2R)-2-\{[2-Amino-5-(benzyloxy)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino\}-4-
     methylpentan-1-ol;
     (2R)-2-(2-Amino-5-[(3-methoxybenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-7-yl\{amino\}-4-
5
     methylpentan-1-ol;
     (2R)-2-\{[2-Amino-5-(2-phenylethoxy)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino<math>\}-4-
     methylpentan-1-ol;
      (2R)-2-\{[2-Amino-5-(2-phenoxyethoxy)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino}-4-
10
     methylpentan-1-ol;
      (2R)-2-[\{2-Amino-5-[(2-methylbenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-7-
      yl}(methyl)amino]-4-methylpentan-1-ol;
      (2R)-2-[\{2-Amino-5-[(4-chlorobenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-7-
     yl}(methyl)amino]-4-methylpentan-1-ol;
15
     (2R)-2-[{2-Amino-5-[(3-chlorobenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-7-
      yl}(methyl)amino]-4-methylpentan-1-ol;
      (2R)-2-[\{2-\text{amino-}5-[(2-\text{methoxybenzyl})\text{oxy}][1,3]thiazolo[4,5-d]pyrimidin-7-
      yl}(methyl)amino]-4-methylpentan-1-ol;
      (2R)-2-[[2-Amino-5-(benzyloxy)[1,3]thiazolo[4,5-d]pyrimidin-7-yl](methyl)amino]-4-
20
     methylpentan-1-ol;
      (2R)-[{2-Amino-5-[(4-bromo-2-fluorobenzyl)-(R_S,S_S)-sulfinyl][1,3]thiazolo[4,5-
      d|pyrimidin-7-yl}(methyl)amino]-4-methylpentan-1-ol;
      (2R)-2-[(2-Amino-5-\{[2-(4-bromophenyl)ethyl]-(R_S,S_S)-sulfinyl\}[1,3]thiazolo[4,5-
      d|pyrimidin-7-yl)amino]-4-methylpentan-1-ol;
25
     (2R)-2-[(2-Amino-5-\{[2-(2-bromophenyl)ethyl]-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl\}][1,3]thiazolo[4,5-
      d|pyrimidin-7-yl)amino|-4-methylpentan-1-ol;
      (R)-2-[(2-Amino-5-{[2-(2-bromophenyl)ethyl]-(R_S,S_S)-sulfinyl}[1,3]thiazolo[4,5-
      d]pyrimidin-7-yl)(methyl)amino]-4-methylpentan-1-ol;
      2-[(2,3-Difluorobenzyl)oxy]-4-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}pteridin-
30
      7(8H)-one;
      4-{[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino}-2-[(3-methoxybenzyl)oxy]pteridin-
      7(8H)-one;
```

- 2-[(2-Chloro-3-methoxybenzyl)oxy]-4-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}pteridin-7(8H)-one;
- $4-\{[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino}-2-(2-phenylethoxy)pteridin-7(8H)-one;$
- 5 4-{[(1*R*)-1-(Hydroxymethyl)-3-methylbutyl]amino}-2-(2-phenoxyethoxy)pteridin-7(8*H*)-one;
 - 2- $[(2-Chlorobenzyl)oxy]-4-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}pteridin-7(8H)-one;$
 - $2-[(4-Chlorobenzyl)oxy]-4-\{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino\} pteridinal properties of the properties of the$
- 10 7(8H)-one;
 - 4-{[(1*R*)-1-(Hydroxymethyl)-3-methylbutyl]amino}-2-[(4-methylbenzyl)oxy]pteridin-7(8*H*)-one;
 - 4-{[(1*R*)-1-(Hydroxymethyl)-3-methylbutyl]amino}-2-[(3-methylbenzyl)oxy]pteridin-7(8*H*)-one;
- 2-[(3-Chlorobenzyl)oxy]-4-{[(1*S*,2*S*)-2-hydroxy-1-(hydroxymethyl)propyl]amino}-7-oxo-7,8-dihydropteridine-6-carboxamide;
 - 2- $[(2,3-Difluorobenzyl)-(R_s,S_s)-sulfinyl]-4-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}pteridin-7(8H)-one;$
 - 5-(Benzyloxy)-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-
- 20 d]pyrimidin-2(3H)-one;
 - 7-{[(1*R*)-1-(Hydroxymethyl)-3-methylbutyl]amino}-5-[(3-methoxybenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;
 - 7-{[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino}-5-(2-phenylethoxy)[1,3]thiazolo[4,5-
- 25 d]pyrimidin-2(3H)-one;
 - 5-(Benzyloxy)-7-{[(1R)-1-(hydroxymethyl)butyl]amino}[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one;
 - 7- $\{[(1R)-1-(Hydroxymethyl)butyl]amino\}-5-\{[(1S)-1-phenylethyl]oxy\}[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one;$
- 30 *N*-(3-{[(7-{[(1*R*)-1-(Hydroxymethyl)butyl]amino}-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-*d*]pyrimidin-5-yl)oxy]methyl}phenyl)-*N*-methylmethanesulfonamide;

- $N-(3-\{[(7-\{[(1R)-1-(Hydroxymethyl)-2-methylpropyl]amino}-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-d]pyrimidin-5-yl)oxy]methyl\}phenyl)-methanesulfonamide; 5-(Benzyloxy)-7-{[1-(hydroxymethyl)cyclopentyl]amino}-[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one;$
- 5 7-{[1-(Hydroxymethyl)cyclopentyl]amino}-5-[(2-methylbenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;
 - 7-{[1-(Hydroxymethyl)cyclopentyl]amino}-5-[(3-methylbenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;
 - 5-[(2-Chlorobenzyl)oxy]-7-{[1-(hydroxymethyl)cyclopentyl]amino}[1,3]thiazolo[4,5-
- 10 d]pyrimidin-2(3H)-one;
 - 5-[(3-Chlorobenzyl)oxy]-7-{[1-(hydroxymethyl)cyclopentyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;
 - 5-[(4-Chlorobenzyl)oxy]-7-{[1-(hydroxymethyl)cyclopentyl]amino}[1,3]thiazolo[4,5-d]pyrimidin-2(3*H*)-one;
- 7-{[1-(Hydroxymethyl)cyclopentyl]amino}-5-[(2-methoxybenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-2(3*H*)-one;
 - 7-{[1-(Hydroxymethyl)cyclopentyl]amino}-5-[(3-methoxybenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one;
 - 4-{[(7-{[1-(Hydroxymethyl)cyclopentyl]amino}-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-
- 20 d]pyrimidin-5-yl)oxy]methyl}benzonitrile;
 - (*R*,*S*)-7-[[1-(Hydroxymethyl)cyclopentyl]amino]-5-(1-phenylethoxy)-thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;
 - 7-{[1-(Hydroxymethyl)cyclopentyl]amino}-5-{[(1S)-1-phenylethyl]oxy}[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one;
- 5- $\{[2-(3-\text{Chlorophenyl})-(R_S, S_S)-\text{ethyl}]\text{sulfinyl}-7-\{[(1R)-1-(\text{hydroxymethyl})-3-\text{methylbutyl}]\text{amino}\}[1,3]\text{thiazolo}[4,5-d]\text{pyrimidin-2}(3H)-one;}$
 - 5- $\{[2-(2-Bromophenyl)ethyl]-(R_S,S_S)-sulfinyl\}-7-\{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino\}[1,3]thiazolo[4,5-<math>d$]pyrimidin-2(3H)-one;
 - 5-[(2,3-Difluorobenzyl)-(R_S , S_S)-sulfinyl]-7-{[(1R)-1-(hydroxymethyl)-3-
- 30 methylbutyl]amino}[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one; 5-[Benzyl-(R_S , S_S)-sulfinyl]-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one;

Attorney Docket No. 101219-1P US US Application No.: 10/575,534

5-[(2-Chlorobenzyl)-(R_S , S_S)-sulfinyl]-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one; 5-[(4-Chlorobenzyl)-(R_S , S_S)-sulfinyl]-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one;

5 5-[Benzyl-(R_S , S_S)-sulfinyl]-7-{[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino}[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one; or a pharmaceutically acceptable salt thereof.